8-K: Profound Medical Q2 2025: Flat Revenue, Wider Loss

Profound Medical Corp. reported flat revenue of $2.2 million and a widened net loss of $15.7 million for Q2 2025, despite growing TULSA-PRO system utilization and pipeline.

Summary

• Q2 2025 revenue was approximately $2.2 million, essentially unchanged from the same three-month period a year ago.
• Recurring non-capital revenue, including consumables, leases, and services, was $1.6 million, while capital equipment sales were $650,000.
• Gross margin for Q2 2025 improved to 73%, up from 64% in the prior year, primarily due to higher manufacturing efficiency.
• Total operating expenses increased significantly to approximately $15.4 million in Q2 2025, compared with $9.3 million in the prior year period.
• Net loss for Q2 2025 was approximately $15.7 million, or $0.52 per common share, widening from $6.9 million, or $0.28 per common share, in Q2 2024.
• Cash balance as of June 30, 2025, was approximately $35.2 million, down from $54.9 million at December 31, 2024.
• Same-store TULSA-PRO procedure volumes increased 10% sequentially from Q1-2025.
• The TULSA-PRO qualified sales pipeline now stands at 80 new systems in the Verify, Negotiate, and Contracting stages.
• The new TULSA-AI Volume Reduction Module for BPH treatment was successfully used commercially in June 2025, with a full launch expected in Q4-2025.
• Integration of TULSA-PRO with Siemens Healthineers Magnetom Free.Max MR scanner remains on track for sales initiation before the end of 2025.
• Management anticipates achieving total year-over-year revenue growth in the approximate range of 70% to 75% in 2025.

Sentiment

Score: 4

Explanation: While there are positive operational developments like pipeline growth, increased procedure volumes, and promising clinical data, the flat revenue and significantly widened net loss, coupled with a substantial increase in operating expenses and cash burn, indicate significant financial challenges and execution risks. The miss on internal revenue targets due to sales delays is a concern, despite management's optimistic full-year guidance.

Positives

• Same-store TULSA-PRO procedure volumes increased 10% sequentially from Q1-2025, indicating growing utilization of existing systems.
• The qualified TULSA-PRO sales pipeline is robust, with 80 new systems classified within the Verify, Negotiate, and Contracting stages.
• Gross margin expanded to 73% in Q2 2025, up from 64% in the prior year, driven by improved manufacturing efficiency.
• Initial perioperative data from the CAPTAIN randomized trial demonstrated that MRI-guided TULSA provided statistically significant improvement in post-operative experience (no blood loss, no overnight stay, reduced pain, faster recovery) compared to robotic radical prostatectomy.
• The first commercial BPH treatment utilizing the new TULSA-AI Volume Reduction Module was successfully conducted, with the module designed to shorten treatment duration for BPH patients.
• Integration of TULSA-PRO and Siemens Healthineers Magnetom Free.Max MR scanner is on track for sales initiation before the end of 2025, potentially expanding market reach.
• Shareholders approved all matters put forward at the Annual General and Special Meeting, including the election of six nominees to the board of directors.
• Leonard Wheeler, a former NFL player and TULSA procedure patient, was named Global Ambassador for TULSA-PRO to drive global awareness and advocacy.

Negatives

• Q2 2025 revenue of $2.2 million was essentially unchanged from the prior year period, falling short of management's internal expectation of over $3 million due to short-term sales delays.
• Net loss significantly widened to $15.7 million ($0.52 per common share) in Q2 2025, compared to $6.9 million ($0.28 per common share) in Q2 2024.
• Total operating expenses increased substantially to $15.4 million in Q2 2025, up from $9.3 million in Q2 2024, driven by increased headcount, CAPTAIN trial enrollment, sales force expansion, commissions, travel, and infrastructure costs.
• Cash balance decreased to $35.2 million as of June 30, 2025, from $54.9 million at December 31, 2024, indicating significant cash burn.
• Net cash used in operating activities for the six months ended June 30, 2025, was $22.027 million, more than double the $10.748 million used in the same period in 2024.

Risks

• Risks inherent in the medical device industry.
• Challenges related to regulatory approvals.
• Uncertainties regarding reimbursement policies.
• Impact of broader economic factors.
• General risks associated with equity markets.
• Risks linked to company growth and market competition.
• Factors that could cause actual actions, events, or results to differ materially from forward-looking statements.

Future Outlook

Management anticipates achieving total year-over-year revenue growth in the approximate range of 70% to 75% in 2025, driven by a large and growing TULSA-PRO system capital sales pipeline and strong TULSA procedure volume growth. The full launch of the TULSA-AI Volume Reduction module is expected in Q4-2025, and sales of the combined TULSA-PRO and Siemens Healthineers Magnetom Free.Max MR scanner solution are on track to initiate before the end of 2025.

Management Comments

• "The second quarter was characterized by some unfortunate timing, as we experienced what we believe are short-term delays in completing a few TULSA-PRO capital sales."
• "Had these occurred in the quarter, total revenues would have been over $3 million."
• "With this, combined with our large and growing TULSA-PRO system capital sales pipeline, and the strong TULSA procedure volume growth we are seeing, we continue to work towards achieving total year-over-year revenue growth at an approximate range of 70% to 75% in 2025."

Industry Context

Profound Medical operates in the competitive medical device industry, specializing in incision-free therapies for diseased tissue, particularly prostate conditions. The company's TULSA-PRO system, which combines real-time MRI, AI-enhanced planning, and robotic ultrasound, aligns with the broader healthcare trend towards less invasive, precision-guided treatments. The development of the TULSA-AI Volume Reduction module for BPH and the partnership with Siemens Healthineers for MR scanner integration demonstrate efforts to enhance product offerings and expand market reach within the urology and broader medical imaging sectors. The positive clinical trial data comparing TULSA to robotic radical prostatectomy suggests a potential for TULSA-PRO to gain significant traction as a mainstream treatment modality, challenging traditional surgical approaches.

Comparison to Industry Standards

• The CAPTAIN randomized trial data indicates that TULSA-PRO offers statistically significant improvements in post-operative experience (e.g., no blood loss, no overnight stay, reduced pain, faster recovery) compared to robotic radical prostatectomy (RP), a common surgical intervention for prostate cancer. This positions TULSA-PRO as a potentially superior alternative to established invasive procedures.
• The TULSA-AI Volume Reduction module aims to make TULSA-PRO's BPH treatment duration competitive with other existing modalities, addressing a key factor in patient and physician adoption within the BPH treatment market.
• The 73% gross margin achieved in Q2 2025 is strong for a medical device company, suggesting efficient manufacturing operations and potentially favorable pricing power, which could be above industry averages for similar capital equipment and consumable models.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Experienced a significant increase in net loss per share ($0.52 vs $0.28 YoY) and a decrease in cash, which could raise concerns about profitability and liquidity. However, the growing sales pipeline and positive clinical data offer potential for future growth.
• Patients: Benefit from the TULSA-PRO system's incision-free, precise treatment for prostate conditions, with new data showing improved post-operative experience compared to traditional surgery. The TULSA-AI Volume Reduction module aims to improve treatment efficiency for BPH patients.
• Employees: Increased headcount and sales force expansion indicate growth in employment opportunities, but the widening losses could put pressure on future hiring or compensation.
• Customers (Hospitals/Clinics): Continued growth in TULSA-PRO utilization and a strong sales pipeline suggest increasing adoption of the system. The TULSA-AI module and Siemens partnership enhance the product offering.
• Creditors: The decrease in cash and increased net loss could be a point of monitoring, though the company still holds $35.2 million in cash.

Next Steps

• Full launch of the TULSA-AI Volume Reduction module in Q4-2025.
• Initiation of sales for the combined TULSA-PRO and Siemens Healthineers Magnetom Free.Max MR scanner solution before the end of 2025.
• Continue working towards achieving total year-over-year revenue growth at an approximate range of 70% to 75% in 2025.
• Ongoing enrollment and treatments for the CAPTAIN trial.

Key Dates

Recommendation

While Profound Medical shows promising operational progress with growing TULSA-PRO utilization, a strong sales pipeline, positive clinical trial data, and strategic partnerships (Siemens, TULSA-AI module), the financial results for Q2 2025 are concerning. Flat revenue year-over-year, a significant widening of the net loss, and a substantial increase in operating expenses indicate a high cash burn rate and a lack of immediate profitability. The company missed its internal revenue target due to sales delays, which raises questions about execution. The long-term potential of TULSA-PRO is evident, but the current financial performance suggests a 'hold' position until there is clear evidence of revenue acceleration and a path towards reduced losses and improved cash flow, aligning with management's ambitious full-year revenue growth guidance.

Keywords

Profound Medical, TULSA-PRO, Prostate Cancer, BPH, Medical Device, Ablation Therapy, MRI-guided, Ultrasound, Urological, Sonalleve, Uterine Fibroids, Bone Metastases, Healthcare Technology, NASDAQ:PROF, TSX:PRN